Mauro Papotti

Endocrine pathology · 2001–2022

A researcher in the Science corpus: 8 papers; trusts 0 researchers and is trusted by 0 researchers here, as inferred from the citation graph.

Papers from Mauro Papotti's perspective

Ordered by how strongly the researchers Mauro Papotti trusts endorse each paper. Same corpus, a different order for every researcher.

  1. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. (European Journal of Endocrinology)
  2. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. (Journal of Clinical Endocrinology and Metabolism)
  3. Extent of Surgery Affects Survival for Papillary Thyroid Cancer (Annals of Surgery)
  4. Sorafenib in locally advanced or metastatic, radioactive iodine-refractory, differentiated thyroid cancer: a randomized, double-blind, phase 3 trial (The Lancet)
  5. BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. (Journal of Clinical Oncology)
  6. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. (New England Journal of Medicine)
  7. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). (European Journal of Cancer)
  8. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. (The Lancet)
  9. The Effect of Advances in Lung-Cancer Treatment on Population Mortality (New England Journal of Medicine)
  10. Guidelines for radioiodine therapy of differentiated thyroid cancer (European Journal of Nuclear Medicine and Molecular Imaging)

Their papers